CN1045718C - New medical use for cucoline - Google Patents
New medical use for cucoline Download PDFInfo
- Publication number
- CN1045718C CN1045718C CN95113774A CN95113774A CN1045718C CN 1045718 C CN1045718 C CN 1045718C CN 95113774 A CN95113774 A CN 95113774A CN 95113774 A CN95113774 A CN 95113774A CN 1045718 C CN1045718 C CN 1045718C
- Authority
- CN
- China
- Prior art keywords
- drug
- present
- addiction
- sinomenine
- breaking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicinal use of a material, particularly to the use of a compound, sinomenine for preparing drug-breaking medicine. The present invention mainly overcomes the defect that available drug-breaking medicines have addiction and side effects. Because of having the similar structural formula and functions with morphine and no addiction, sinomenine is used to prepare drug-breaking medicines. The preparation method of the present invention comprises the following step: sinomenine is pulverized, sieved and sterilized to obtain drug-breaking medicine powder. The clinic results show that the present invention can obviously relieve and eliminate the abstention symptoms without medicinal dependency and addiction. After treated for 7-12 days, a general drug-addict can have the addiction dropped, and the curative effect manifestation rate of the present invention is 92.2%.
Description
The present invention relates to the application in the preparation drug-breaking medicine of a kind of medical usage of chemical compound, particularly sinomenine.
As everyone knows, drug abuse is the infringement health of human body, wrecks the bad habit of life.According to national interrelated data, China about people more than 320,000 that is being addicted to drug, serious harm social order, brokenly encircled spiritual civilization, the various crime rates of Yin Faing are still in continuous growth therefrom.So drug rehabilitation is an extremely important and urgent social problem.At present, the anti-additive medicament that each narcotic house adopts mainly contains three kinds: (1) dihydroetorphine hydrochlorate, this medicine is artificial synthetic drug, main effect is to substitute drugs, because its psychic dependence is 100 times of morphine, thereby in drug addiction treatment addiction very easily, become and behind drugs, second rely on medicine; (2) Mei Shadong, this medicine also belongs to the synthetic medicine, equally also has addiction; (3) do not have addiction drug-dropping tablet (phenylamino imidazoline) fast, the former hypertension that is used for the treatment of of this medicine does not have addiction though this medicine is used for drug addiction treatment, exists patient's blood pressure is obviously descended the deficiency that side effect is big.
The purpose of this invention is to provide a kind of do not have addiction and the little application of medicine in the preparation drug-breaking medicine of side effect.
Realize that the object of the invention technical scheme is to use the medicine of sinomenine as preparation drug rehabilitation usefulness.Sinomenine is separating obtained from menispermaceae plant Caulis Sinomenii rhizome, has pharmacological actions such as antiinflammatory, calmness, analgesia, antitussive, spasmolytic, is applied to treating rheumatoid arthritis clinically.In view of sinomenine chemical constitution and morphine approximate, but addicted characteristics of tool not, the present invention uses the application of sinomenine as the preparation drug-breaking medicine.Its preparation method is that sinomenine is pulverized, and sieves, sterilizes to make and treat the powder medicine of quitting drug abuse with 100 mesh sieves.
One of important feature of the present invention is that toxicity is little, sees Table 1 acute zoopery and sub-acute toxicity test respectively.
(1) acute toxicity test.
10 one group of mice, male and female half and half, after trial test, selected 4-5 dosage group, promptly observe after the mice administration toxicity anti-main should, dead mouse number in the continuous record 7 days, and through BLiss method mensuration LD
50Dosage, it the results are shown in Table 1.
Chmice acute toxicity test table 1
| Route of administration | Dosage (mg/kg) | The experiment number | Death toll | LD 50(mg/kg) (95% fiducial limit) |
| Subcutaneous | 350 400 450 500 | 10 10 10 10 | 1 2 6 8 | 439 (410-471) |
| Per os | 600 650 700 750 800 | 10 10 10 10 10 | 1 4 6 8 9 | 685 (652-719) |
(2) subacute toxicity test
With 15 body weight is rat childhood of 44～53 grams, with 5 is one group, sinomenine of lumbar injection every day, the first group is given 40 milligrams/kilogram, and the second group is given 80 milligrams/kilogram, and third group of feedwater in contrast, continuous 14 days, three treated animals are at body weight gain, food-intake, hemogram and general situation, the equal no significant difference in internal organs pathological section aspect.
Two of important feature of the present invention is that the chemical constitution of sinomenine is close with morphine, and all has analgesia, antitussive, calmness, and pharmacological actions such as excited spinal cord see Table 2.The chemical constitution comparison sheet 2 of sinomenine and morphine
Three of important feature of the present invention is that sinomenine does not have addiction, sees following experimental result:
Four body weight 4.5-7kg of monkey, experimental group subcutaneous administration 5mg/kg/ day begins to increase to 80mg/kg/ day, no withdrawal symptom and any unusual performance in 72 hours after successive administration 39 days, 45 days, the observation drug withdrawal, matched group awards the drug withdrawal after 39 days and 45 days of morphine hydrochloride successive administration, occur remarkable dyspnea after drug withdrawal in 24 hours, the expression withdrawal symptom such as gruel that withers lasts 72 hours.
The clinical use result of the present invention shows that following advantage is arranged:
1. the present invention is from the non-spiritual narcoticness drug-breaking medicine of a kind of pure natural that forms from the menispermaceae plant extract, and human body is not had obvious toxic and side effects.
2. the present invention has obvious alleviation and removes the withdrawal symptom that junkie termination drugs contact the back appearance, can improve central nervous system's metabolism, promotes antisecosis.
3. phenomenon such as no drowsiness, disturbance of consciousness is negative through pharmacokinetics check addicted substance metabolite after the medication of the present invention, no drug dependence and addiction.
4. need not special care in the treatment, the drug abuse patient can reach the purpose of withdrawal, drug rehabilitation through behind 7-12 days the general treatment under the situation without any misery.
For showing curative effect, the present invention is qualitative about the definition and the urine morphine of drug dependence according to The World Health Organization (WHO), makes a definite diagnosis and select opioid drug dependent patient 32 examples, age 21-31 year, male's 22 examples wherein, age 21-36 year; Women's 10 examples, 22-31 year.Be and scald opium eating class drug dependence person, history of drug abuse is 2-84 month.Whole be a cup too low disease and infectious disease of cases, and get rid of other body complication, do not pass through the other medicines withdrawal and treatment yet.Its observational technique adopts: (1) CINA (the narcotic withdrawal symptom is estimated scale) physical dependence is estimated scale, and the health withdrawal symptom is observed day by day and marked before treatment and in treating; (2) range estimation scale, health check-up every day, and observe the crave for degree of patient to used medicine; (3) intend the toxic and side effects that the observation post day by day of adverse effect scoring causes with medicine certainly.
Medication: the powder of will quitting drug abuse places Xi Bo to go up heating, makes powder become liquid, and the smog continuously of pressing ascension with paper tube hard sucks rapidly, each 20-60mg, and every day three times, 10-15 days is a drug treatment, clinical test results such as table 3, table 4, table 5.
Medicine control withdrawal symptom is efficacy result (N=32) table 3 day by day
Compare (N=32) table 4 in the treatment of medicine control withdrawal symptom with before the treatment
32 routine patients drug rehabilitation in 12 days symptom curative effect information slip table 5
| The treatment date | X±S | |
| In the treatment | D before the treatment 1 d 2 d 3 d 4 d 5 d 6 d 7 d 8 d 9 d 10 d 11 d 12 | 24.63±2.68 15.94±4.72 12.41±5.13 10.03±4.20 8.16±3.96 7.44±4.15 7.75±4.31 6.09±3.95 4.03±3.35 3.40±3.23 2.06±2.03 1.63±1.45 1.00±1.21 |
| Treatment time | Equal value difference | Standard deviation | Standard error | Probability |
| 72 hours 12 days | 14.954 23.625 | 2.826 3.976 | 0.499 0.685 | P＜0.0001 P＜0.0001 |
| Symptom example number appears before the treatment | Treat 12 days routine digital displays and imitate effective obvious effective rate (%) | |
| Perspire to have the fidgets the trembling nasal obstruction yawn belly of shedding tears of n and V goose pimples changes body temperature myalgia heart rate | 32 32 32 32 32 32 32 32 32 32 32 32 | 30 2 93.8 29 3 90.6 30 2 93.8 26 6 81.3 32 0 100 32 0 100 32 0 100 28 4 87.5 28 4 87.5 29 3 90.6 26 6 81.3 32 0 100 |
Table 3, table 4 can obviously suppress the generation and the extent of reaction of withdrawal symptom as can be seen after the medication, 72 hours and treat not phase efficacy result and treatment before difference highly significant (P＜0.0001) relatively.
Table 5 shows that various withdrawal symptoms all have remarkable minimizing after treating 72 hours.Wherein be effectively with the remission, symptom is removed and is produce effects, and all patients are all effective through treatment.
Clinical observation result shows: (1) dosage can show the curative effect of controlling withdrawal symptom at 120mg/ in day, with the increase curative effect raising of dosage.And in used dosage, even 100mg/ time does not produce the euphoriant effect of opioid drug yet, the close medicine degree of using range estimation analogy scale to observe user is to successively decrease successively with Time of Administration, stops using to 12 days, the patient does not have tangible withdrawal symptom and exists, and it all is negative that the urine morphine is measured; (2) can alleviate or remove anxiety after patient's medication, fidgety, pain etc. are subjective uncomfortable, its therapeutic efficiency reaches 92.2% does not have obviously stomachache, the common complication of giving up such as cough, abundant expectoration, (3) administering mode adopts to scald and sucks, satisfied the psychological need of drug abstainer, the patient takes like a shot in the treatment, and not having has drug dependence.
Claims (1)
1. a chemical compound sinomenine is characterized in that can be used as the preparation drug-relief medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95113774A CN1045718C (en) | 1995-11-06 | 1995-11-06 | New medical use for cucoline |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95113774A CN1045718C (en) | 1995-11-06 | 1995-11-06 | New medical use for cucoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1149456A CN1149456A (en) | 1997-05-14 |
| CN1045718C true CN1045718C (en) | 1999-10-20 |
Family
ID=5080086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95113774A Expired - Fee Related CN1045718C (en) | 1995-11-06 | 1995-11-06 | New medical use for cucoline |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1045718C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038567A (en) * | 2010-11-08 | 2016-10-26 | 奥默罗斯公司 | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| CN103127308B (en) * | 2013-02-06 | 2015-04-15 | 王凯 | Detoxification medicament used for treating morphine type drug addiction and preparation thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6421845A (en) * | 1987-07-17 | 1989-01-25 | Ricoh Kk | Method of electrodeposition |
| JPH0210153A (en) * | 1988-06-28 | 1990-01-12 | Mitsubishi Electric Corp | Ultrasonic flaw detecting system |
| JPH0210217A (en) * | 1988-06-29 | 1990-01-16 | Yuichi Moriki | Detecting piece of magnetic sensor |
-
1995
- 1995-11-06 CN CN95113774A patent/CN1045718C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6421845A (en) * | 1987-07-17 | 1989-01-25 | Ricoh Kk | Method of electrodeposition |
| JPH0210153A (en) * | 1988-06-28 | 1990-01-12 | Mitsubishi Electric Corp | Ultrasonic flaw detecting system |
| JPH0210217A (en) * | 1988-06-29 | 1990-01-16 | Yuichi Moriki | Detecting piece of magnetic sensor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1149456A (en) | 1997-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ford et al. | Reinforcing properties of intravenous procaine in rhesus monkeys | |
| Rasor et al. | Addiction to meperidine (Demerol) hydrochloride | |
| AU1915192A (en) | Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins | |
| CN1045718C (en) | New medical use for cucoline | |
| CN104706881B (en) | A kind of health products with regulation sleep function | |
| CN107375574A (en) | A kind of Chinese medicine composition for treating cardiac neurosis and its application | |
| CN1215874C (en) | Medicine for resolving sputum and relieving asthma and cough, preparing process thereof | |
| CN100457144C (en) | Compound capsule of Chinese date kernel, and preparation method | |
| CN101653573A (en) | Traditional Chinese medicine preparation for treating insomnia | |
| Field Jr et al. | Pellagra in the Average Population of the Northern States | |
| CN1052419C (en) | Herb medicine for treating diabetes mellitus | |
| CN100372553C (en) | Tranquilizing and blood nourishing oral liquid | |
| CN108186954A (en) | A kind of relieving cough and reducing sputum Chinese medicine and preparation method thereof | |
| CN1840121A (en) | Medicine for treating cough and preparation method thereof | |
| CN1210057C (en) | Blood lipid capsule and its preparing method | |
| Harrison et al. | Pethidine in sickle cell crisis. | |
| Krueger | Narcotics and analgesics | |
| CN1768746A (en) | New medical application of matrine alkaloid | |
| Mohan et al. | A Comparative Study Of Amlapittavinashak Yoga Kwath & Bhunimbadi Kwath In The Management Of Amlapitta WSR To Acid Peptic Diseases. | |
| CN108553528A (en) | Anti-additive medicament and preparation method thereof | |
| CN1265834C (en) | Chinese medicine against drug dependence | |
| CN100342904C (en) | Pure natural drug relief medicine | |
| CN115137789A (en) | Composition for improving sleep function and preparation method and application thereof | |
| CN1511554A (en) | Medicinal composition for treating diabetes | |
| MAYER et al. | BARBITURATE POISONING: Report of Three Cases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: XI AN HI-TECH INDUSTRIAL CO., LTD. TIANCHENG PHARM Free format text: FORMER NAME OR ADDRESS: TIANCHENG MEDICAL BIOLOGICAL ENGINEERING CO., LTD., XI AN |
|
| CP01 | Change in the name or title of a patent holder |
Patentee after: Xi'an hi tech Industrial Limited by Share Ltd Tiancheng medical and biological engineering company Patentee before: Tiancheng Medicine Biological Engineering Co., Ltd., Xi'an |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |